Big Pharma must not have its profits impacted. More dangerous than ivomectrin you know.
Over-the-counter aspirin could protect the lungs of COVID-19 patients and minimize the need for mechanical ventilation, according to
new research at the George Washington University.
The team investigated more than 400 COVID patients from hospitals across the United States who take aspirin unrelated to their COVID disease, and found that the treatment
reduced the risk of several parameters by almost half: reaching mechanical ventilation by 44%, ICU admissions by 43%, and overall in-hospital mortality by 47%.
Israeli researchers reached similar results in a preliminary trial at the Barzilai Medical Center in March. In addition to its effect on blood clots, they found that aspirin carried immunological benefits and that
the group taking it was 29% less likely to become infected with the virus in the first place.
The treatment reduced the risk of reaching mechanical ventilation by 44%. ICU admissions were lower by 43%, and an overall in-hospital mortality saw a 47% decrease.
www.jpost.com